Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

FDA approvals 2017

- PMLiVE

CURx buys rights to Gilead’s lung infection drug

Agrees deal for fosfomycin/tobramycin combination

- PMLiVE

Mylan to sell Gilead’s medicines in India

Includes HIV treatments Viread, Truvada and Stribild

- PMLiVE

Kite Pharma appoints head of regulatory affairs

Rizwana Sproule joins from Amgen

- PMLiVE

EU clears Gilead’s hepatitis C therapy Sovaldi

Region’s first all-oral treatment approved to treat the virus

- PMLiVE

FDA sets standard review for Gilead’s idelalisib in NHL

Comes despite accelerated review for drug’s use in chronic lymphocytic leukaemia

Kite Pharma names Cynthia Butitta as CFO

She helped broker Pfizer’s takeover of NextWave Pharmaceuticals

- PMLiVE

CHMP recommends Gilead’s sofosbuvir for hep C

Set to be first interferon-free treatment regime

- PMLiVE

Gilead’s sofosbuvir aces FDA advisory committee

On track for hepatitis C approval in US

- PMLiVE

Gilead halts leukaemia study on positive results

Idelalisib provides significant benefit in chronic lymphocytic leukaemia

- PMLiVE

Boehringer’s first cancer drug leads EMA recommendations

Afatinib recommended for lung cancer under brand name Giotrif

- PMLiVE

Gilead launches combination HIV pill in UK and Germany

Stribild is approved in EU as once-daily single tablet

- PMLiVE

Gilead files oral hepatitis C drug sofosbuvir in US

Could be part of first all-oral regimen for virus

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links